The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Capricor Therapeutics announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne ...
Capricor Therapeutics Inc. (NASDAQ:CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock ...
Capricor Therapeutics is seeking FDA approval for CAP-1002, targeting heart function in Duchenne Muscular Dystrophy (DMD) patients, with a PDUFA date in August 2025. Despite promising science, ...
FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- Capricor Therapeutics (NASDAQ: CAPR) today announced the successful completion of a ...
Capricor Therapeutics has filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD cardiomyopathy, with strong FDA recognition. Deramiocel's efficacy was ...
In male patients with DMD, treatment with deramiocel reduced upper limb function deterioration compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...
Tuesday, Capricor Therapeutics Inc (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company, for the commercialization and distribution in ...
LV end systolic volume, indexed (mL/m2 )-2.4-5.1 LV end diastolic volume, indexed (mL/m2)-5.7-10.0 *Baseline is referred to as start of HOPE-2 study, changes in medians are shown; 3-year timepoint on ...
Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results